|Chelsea Therapeutics International Ltd.|
3530 Toringdon Way
United States - Map
Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. It is developing Northera (droxidopa), a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (Neurogenic OH) in patients with primary autonomic failure, dopamine-ß-hydroxylase, and deficiency and non-diabetic autonomic neuropathy. The company is also evaluating droxidopa in other potentially norepinephrine-related conditions and diseases, including intradialytic hypotension, fibromyalgia, freezing of gait, and adult attention deficit hyperactivity disorders. In addition, it is has a portfolio of metabolically inert antifolates for the treatment of rheumatoid arthritis, as well as for the treatment of multiple other autoimmune disorders, including psoriasis, Crohns diseases, uveitis, ankylosing spondylitis, inflammatory bowel diseases, cancer, and other immunological disorders. The company was founded in 2002 and is headquartered in Charlotte, North Carolina.
|Chelsea Therapeutics International Ltd.’s ISS Governance QuickScore as of Apr 1, 2014 is 3. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 2; Compensation: 6.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Joseph G. Oliveto M.B.A.,
Chief Exec. Officer, Pres and Director
|Mr. J. Nick Riehle MBA,
Chief Financial Officer, Principal Accounting Officer and VP of Admin.
|Dr. L. Arthur Hewitt Ph.D.,
Chief Scientific Officer and VP
|Dr. Michael J. Roberts Ph.D.,
VP of Bus. Devel.
|Mr. Keith W. Schmidt M.B.A.,
Chief Commercial Officer and VP
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|